论文部分内容阅读
目的:观察“通利大肠”对COPD模型大鼠分泌型免疫球蛋白A(SIgA)的影响,从黏膜免疫角度探讨COPD“从肠论治”的效应机制。方法:采用气管注脂多糖加熏香烟联合造模方法建立COPD大鼠模型,随机分为正常组、模型组、治肺组、治肠组及肺肠同治组。正常组、模型组灌胃生理盐水,各给药组灌胃相应中药,连续14天。放射免疫法检测肺泡灌洗液、肠黏膜组织SIgA含量。结果:与正常组比较,模型组大鼠肺泡灌洗液、肠黏膜组织SIgA含量减少(P<0.05)。与模型组比较,治肠组肺泡灌洗液、肠黏膜组织SIgA含量增加(P<0.05)。与治肺组比较,肺肠同治组肺泡灌洗液、肠黏膜组织SIgA含量有所增加(P<0.01)。结论:通利大肠,或在治肺的基础上增加通利大肠,能提高COPD模型大鼠肺泡灌洗液和肠黏膜中SIgA含量,改善COPD大鼠呼吸道和肠道黏膜防御功能,这可能是COPD“从肠论治”效应产生的作用环节之一。
OBJECTIVE: To observe the effect of “Tom Lee” on the secretion of immunoglobulin A (SIgA) in COPD model rats and to explore the mechanism of COPD / “gut rule” from mucosal immunology. Methods: COPD rat models were established by intratracheal injection of lipopolysaccharide and combined with cigarette smoking, and were randomly divided into normal group, model group, treatment of lung group, treatment of intestine group and treatment of lung intestine. Normal group, model group, gavage with saline, each administration group gavage corresponding Chinese medicine, for 14 consecutive days. Radioimmunoassay was used to detect the content of SIgA in alveolar lavage fluid and intestinal mucosa. Results: Compared with normal group, the content of SIgA in alveolar lavage fluid and intestinal mucosa in model group decreased (P <0.05). Compared with model group, the contents of SIgA in alveolar lavage fluid and intestinal mucosa in treatment group were increased (P <0.05). Compared with the treatment group, the content of SIgA in the pulmonary interstitial lavage fluid and intestinal mucosa in the lung-intestine group was increased (P <0.01). CONCLUSION: Tongli’s large intestine or Tongliao’s intestine can increase the content of SIgA in bronchoalveolar lavage fluid and intestinal mucosa in COPD model rats, and improve the respiratory and intestinal mucosal defensive function in COPD rats, which may be COPD “from the bowel governance ” effect of the role of one of the links.